Pathology of the liver sinusoids

Histopathology

Volumn 64, Issue 7, 2014, Pages 907-920

  Brunt, Elizabeth M ^a   Gouw, Annette S H ^b   Hubscher, Stefan G ^c   Tiniakos, Dina G ^d,p   Bedossa, Pierre ^e   Burt, Alastair D ^f   Callea, Francesco ^g   Clouston, Andrew D ^h   Dienes, Hans P ⁱ   Goodman, Zachary D ^j   Roberts, Eve A ^k   Roskams, Tania ^l   Terracciano, Luigi ^m   Torbenson, Michael S ^n,q   Wanless, Ian R ^o  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e BEAUJON HOSPITAL   (France)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j INOVA FAIRFAX HOSPITAL   (United States)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF BASEL   (Switzerland)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o DALHOUSIE UNIVERSITY   (Canada)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q MAYO CLINIC   (United States)

more..

Author keywords

Capillarization; Endothelial cells; Kupffer cells; Liver sinusoids; Space of Disse

Indexed keywords

FIBRIN; VON WILLEBRAND FACTOR;

ANGIOSARCOMA; FIBRIN DEPOSITION; HEMANGIOENDOTHELIOMA; HUMAN; KUPFFER CELL; LANGERHANS CELL HISTIOCYTOSIS; LIVER CELL; LIVER HEMANGIOMA; LIVER HISTOLOGY; LIVER SINUSOID; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STELLATE CELL; ENDOTHELIUM CELL; LIVER; LIVER DISEASE; LIVER VEIN; PATHOLOGY; PHYSIOLOGY; PORTAL VEIN; VASCULARIZATION;

ENDOTHELIAL CELLS; HEPATIC VEINS; HEPATOCYTES; HUMANS; LIVER; LIVER DISEASES; PORTAL VEIN;

EID: 84899960512     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12364     Document Type: Review

References (64)

1. Rubbia-Brandt L, Lauwers GY, Wang H et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56; 430-439.
2. Ryan P, Nanji S, Pollett A et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am. J. Surg. Pathol. 2010; 34; 784-791.
3. Rubbia-Brandt L, Giostra E, Brezault C et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 2007; 18; 299-304.
4. Vauthey J-N, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 2006; 24; 2065-2072.
5. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. 2004; 15; 460-466.
6. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann. Surg. Oncol. 2012; 19; 4287-4299.
7. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br. J. Surg. 2007; 94; 274-286.
8. Mehta NN, Ravikumar R, Coldham CA et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur. J. Surg. Oncol. 2008; 34; 782-786.
9. Tamandl D, Klinger M, Eipeldauer S et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann. Surg. Oncol. 2011; 18; 421-430.
10. Slade JH, Alattar ML, Fogelman DR et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin. Colorectal Cancer 2009; 8; 225-230.
11. Soubrane O, Brouqet A, Zalinski S et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann. Surg. 2010; 251; 454-460.
12. Arnason T, Fleming KE, Wanless IR. Peritumoral hyperplasia of the liver: a response to portal vein invasion by hypervascular neoplasms. Histopathology 2013; 62; 458-464.
13. Hubert C, Sempoux C, Horsmans Y et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007; 27; 938-943.
14. Robinson SM, Mann J, Vasilaki A et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J. Hepatol. 2013; 59; 318-326.
15. Croquelois A, Blindenbacher A, Terracciano L et al. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005; 41; 487-496.
16. Dill MT, Rothweiler S, Djonov V et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 2012; 142; 967-977 e2.
17. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44; 7-14.
18. McLean AJ, Cogger VC, Chong GC et al. Age-related pseudocapillarization of the human liver. J. Pathol. 2003; 200; 112-117.
19. Mak KM, Kwong AJ, Chu E, Hoo NM. Hepatic steatosis, fibrosis and cancer in elderly cadavers. Anat. Rec. (Hoboken) 2012; 295; 40-50.
20. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet 1977; 2; 262-263.
21. Bagheri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann. Intern. Med. 1974; 81; 610-618.
22. Pulliainen AT, Dehio C. Bartonella henselae: subversion of vascular endothelial cell functions by translocated bacterial effector proteins. Int. J. Biochem. Cell Biol. 2009; 41; 507-510.
23. Koehler JE, Sanchez MA, Garrido CS et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N. Engl. J. Med. 1997; 337; 1876-1883.
24. Ross RC, Kovacs K, Horvath E. Ultrastructure of peliosis hepatis in a percutaneous biopsy. Pathol. Eur. 1972; 7; 273-282.
25. Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am. J. Gastroenterol. 1988; 83; 256-261.
26. Zafrani ES, Cazier A, Baudelot AM, Feldmann G. Ultrastructural lesions of the liver in human peliosis. A report of 12 cases. Am. J. Pathol. 1984; 114; 349-359.
27. Feld JJ, Hussain N, Wright EC et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008; 134; 1917-1926.
28. Hussain N, Feld JJ, Kleiner DE et al. Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology 2007; 45; 675-683.
29. Suh N, Liapis H, Misdraji J, Brunt EM, Wang HL. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am. J. Surg. Pathol. 2007; 31; 1403-1409.
30. Cacoub P, Musette P, Descamps V et al. The DRESS syndrome: a literature review. Am. J. Med. 2011; 124; 588-597.
31. Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch. Dis. Child. 2011; 96; 688-693.
32. Lehmberg K, Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br. J. Haematol. 2013; 160; 275-287.
33. Park HS, Kim DY, Lee JH et al. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. Ann. Hematol. 2012; 91; 897-904.
34. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr. Opin. Pediatr. 2012; 24; 9-15.
35. Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND. The canals of Hering might represent a target of methotrexate hepatic toxicity. Am. J. Clin. Pathol. 2004; 121; 324-329.
36. Lafon ME, Bioulac-Sage P, Grimaud JA et al. Perisinusoidal fibrosis of the liver in patients with thrombocytopenic purpura. Virchows Arch. A Pathol. Anat. Histopathol. 1987; 411; 553-559.
37. Harrison SA, Brunt EM, Goodman ZD, Di Bisceglie AM. Diabetic hepatosclerosis: diabetic microangiopathy of the liver. Arch. Pathol. Lab. Med. 2006; 130; 27-32.
38. Roskams T, Baptista A, Bianchi L et al. Histopathology of portal hypertension: a practical guideline. Histopathology 2003; 42; 2-13.
39. Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin. Liver Dis. 1995; 15; 329-339.
40. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82; 291-298.
41. Wilejto M, Abla O. Langerhans cell histiocytosis and Erdheim-Chester disease. Curr. Opin. Rheumatol. 2012; 24; 90-96.
42. Ivan D, Neto A, Lemos L, Gupta A. Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions. Arch. Pathol. Lab. Med. 2003; 127; e337-e339.
43. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am. J. Surg. Pathol. 2008; 32; 615-619.
44. Abdallah M, Genereau T, Donadieu J et al. Langerhans' cell histiocytosis of the liver in adults. Clin. Res. Hepatol. Gastroenterol. 2011; 35; 475-481.
45. Papadakis V, Volonaki E, Katsibardi K et al. A rare case of neonatal systemic xanthogranulomatosis with severe hepatic disease and metachronous skin involvement. J. Pediatr. Hematol. Oncol. 2012; 34; 226-228.
46. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin. Diagn. Pathol. 1990; 7; 19-73.
47. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert. Rev. Hematol. 2010; 3; 497-516.
48. Sanchez-Munoz L, Teodosio C, Morgado JM, Escribano L. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol. 2011; 103; 333-359.
49. Mican JM, Di Bisceglie AM, Fong TL et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22; 1163-1170.
50. Miettinen M, Fletcher CDM, Kindblom LG, Zimmerman A, Tsui WMS. Mesenchymal tumors of the liver. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. Lyon: IARC, 2010; 241-253.
51. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982; 50; 970-981.
52. Ishak KG, Sesterhenn IA, Goodman ZD, Rabin L, Stromeyer FW. Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum. Pathol. 1984; 15; 839-852.
53. Scoazec JY, Degott C, Reynes M, Benhamou JP, Feldmann G. Epithelioid hemangioendothelioma of the liver: an ultrastructural study. Hum. Pathol. 1989; 20; 673-681.
54. Demetris AJ, Minervini M, Raikow RB, Lee RG. Hepatic epithelioid hemangioendothelioma: biological questions based on pattern of recurrence in an allograft and tumor immunophenotype. Am. J. Surg. Pathol. 1997; 21; 263-270.
55. Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours. 4th ed. Lyon: IARC, 2010.
56. Baumhoer D, Tzankov A, Dirnhofer S, Tornillo L, Terracciano LM. Patterns of liver infiltration in lymphoproliferative disease. Histopathology 2008; 53; 81-90.
57. Blakolmer K, Gaulard P, Mannhalter C et al. Unusual peripheral T cell lymphoma presenting as acute liver failure and reappearing in the liver allograft. Transplantation 2000; 70; 1802-1805.
58. Loddenkemper C, Longerich T, Hummel M et al. Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. Virchows Arch. 2007; 450; 493-502.
59. Ponzoni M, Ferreri AJ, Campo E et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J. Clin. Oncol. 2007; 25; 3168-3173.
60. Goodman ZGTL, Wee A. Tumours and tumour-like lesions of the liver. In Burt AD, Portmann BC, Ferrell LD eds. MacSween's pathology of the liver. 6th ed. Edinburgh: Churchill Livingstone, 2012; 761-865.
61. Lu CL, Tang Y, Yang QP et al. Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases. Hum. Pathol. 2011; 42; 1965-1978.
62. Ham MF, Ko YH. Natural killer cell neoplasm: biology and pathology. Int. J. Hematol. 2010; 92; 681-689.
63. Roquet ML, Zafrani ES, Farcet JP, Reyes F, Pinaudeau Y. Histopathological lesions of the liver in hairy cell leukemia: a report of 14 cases. Hepatology 1985; 5; 496-500.
64. Zafrani ES, Degos F, Guigui B et al. The hepatic sinusoid in hairy cell leukemia: an ultrastructural study of 12 cases. Hum. Pathol. 1987; 18; 801-807.